Sigilon Therapeutics, Inc. (SGTX)
| Market Cap | 1.08B |
| Revenue (ttm) | 15.59M |
| Net Income (ttm) | -33.70M |
| Shares Out | 30.19M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | 16.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $34.97 |
| Previous Close | $35.46 |
| Change ($) | -0.49 |
| Change (%) | -1.38% |
| Day's Open | 35.89 |
| Day's Range | 33.38 - 36.32 |
| Day's Volume | 89,002 |
| 52-Week Range | 27.60 - 48.03 |
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 i...
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for...
Cambridge, Massachusetts-based Sigilon was founded to develop its Shielded Living Therapeutics platform which uses advanced techniques to create therapeutic molecules for the treatment of rare...
Sigilon Therapeutics (SGTX) has filed a prospectus for a $100M IPO. The Cambridge, MA-based biotech develops cell therapies based on its Shielded Living Therapeutics (SLTx) platform that combi...
Sigilon Therapeutics, a clinical stage biotech developing molecular therapeutics for chronic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Sigilon Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About SGTX
Sigilon Therapeutics, a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc... [Read more...]
| Industry Biotechnology | IPO Date Dec 4, 2020 |
| CEO Rogerio Vivaldi Coelho | Employees 96 |
| Stock Exchange NASDAQ | Ticker Symbol SGTX |
Financial Performance
In 2019, SGTX's revenue was $14.16 million, an increase of 205.26% compared to the previous year's $4.64 million. Losses were -$43.93 million, 92.9% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 53.75, which is an increase of 53.70% from the latest price.